To test this hypothesis, we investigated whether concomitant overexpression of INHBA and IL13Rα2 in breast cancer patients can be a significant prognostic factor by separating patients based on combined high or low expression levels of IL13Rα2 and INHBA in each patient. Here, IL13RA2 is linked to breast cancer.